Ani Pharmaceuticals (ANIP) Non-Current Debt (2017 - 2026)

Ani Pharmaceuticals has disclosed Non-Current Debt across 10 years of filings, most recently posting $286.0 million for Q1 2026.

• Non-Current Debt for Q1 2026 came in at $286.0 million, down 6.32% year-over-year; the trailing twelve-month figure through Mar 2026 was $286.0 million (down 6.32% YoY), and the FY2025 annual result was $291.8 million, down 5.59% from the prior year.
• Non-Current Debt came in at $286.0 million for Q1 2026 at Ani Pharmaceuticals, down from $291.8 million in the prior quarter.
• In the past five years, Non-Current Debt ranged from a high of $312.9 million in Q3 2024 to a low of $284.4 million in Q2 2024.
• The 5-year median for Non-Current Debt is $286.0 million (2026), against an average of $291.6 million.
• Across the five-year window, Non-Current Debt soared 69.43% in 2022 and retreated 6.32% in 2026, its largest moves.
• Ani Pharmaceuticals' Non-Current Debt stood at $285.7 million in 2022, then slipped by 0.3% to $284.8 million in 2023, then increased by 8.53% to $309.1 million in 2024, then dropped by 5.59% to $291.8 million in 2025, then declined by 2.0% to $286.0 million in 2026.
• The last three Non-Current Debt figures came in at $286.0 million (Q1 2026), $291.8 million (Q4 2025), and $297.7 million (Q3 2025), per Business Quant data.